This page is obsolete: please read the new version.

Binding potential

Binding potential (BP) is the ratio of Bmax (receptor density) to KD (radioligand equilibrium dissociation constant), as defined by Mintun et al. (1984).
BP = Bmax / KD = receptor density x affinity.

In vitro at tracer doses, BP equals the ratio of specifically bound ligand to its free concentration.

In vivo not all of receptors are available for the radioligand to bind because of occupance by endogenous ligands. Therefore, in in vivo imaging the term Bavail is often used instead of Bmax. Assuming that radioligand is not actively transported into tissue, so that at equlibrium the free concentration in plasma (CFP) equals the free concentration in tissue (CFT),
BPF = Bavail / KD = CS / CFT = CS / CFP

In terms of volumes of distribution,
BPF = (VT - VND) / fP
, where VT and VND could be estimated from region-of-interest and reference region, respectively, for example with Logan plot. Calculation of BPF requires plasma sampling and measurement of plasma protein binding (plasma free fraction fP).

Usually, the determination of fP is omitted because it is prone to errors and would merely add more variability to results. Then, the specific binding in tissue is compared to not free but total plasma concentration:
BPP = VT - VND = fP·Bavail / KD

If specific uptake is not compared to plasma concentrations but to non-displaceable tissue uptake, we can determine BPND:
BPND = (VT - VND) / VND = VT / VND - 1
, where the term VT / VND is often referred to as distribution volume ratio (DVR). DVR can be estimated without plasma sampling using for example (simplified) reference tissue compartment model or Logan plot with reference tissue input. However, BPND could also be calculated from distribution volumes that are estimated using plasma sampling.


See also:



References:

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27(9): 1533-1539.

Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984; 15: 217-227.

Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl. Med. Biol. 2001; 28: 595-608.



Valid XHTML 1.0 Strict Valid CSS! Creative Commons License